BioTech Social Media and Updates

Aging Shares Disease Hallmarks, May Be Treatable
SocialApr 12, 2026

Aging Shares Disease Hallmarks, May Be Treatable

Is aging a disease? These authors reflect: “Disease is commonly defined as an abnormality of bodily structure or function, distinct from direct physical injury (Bulterijs et al., 2015). Whether ageing itself constitutes a disease has long been debated in the fields of...

By David Barzilai, MD PhD
Therapeutic Phlebotomy Restores Bone Marrow, Reverses Aging
SocialApr 12, 2026

Therapeutic Phlebotomy Restores Bone Marrow, Reverses Aging

Periodic Therapeutic Phlebotomy Mitigates Systemic Aging Phenotypes by Promoting Bone Marrow Function “our work provides preliminary evidence suggesting that periodic therapeutic phlebotomy exerts anti-aging effects by restoring bone marrow function and mitigating aging phenotypes, subsequently driving peripheral blood functional restoration.” 👉 “...

By David Barzilai, MD PhD
Safe Cell Reprogramming Restores Identity, Nature Reports
SocialApr 12, 2026

Safe Cell Reprogramming Restores Identity, Nature Reports

You're confused. Let me explain: My student @Y_Ryan_Lu worked for years to find a SAFE way to reprogram cells so they'd only RE-GAIN identity, not LOSE it, as Prof Yamanaka showed We tried innumerable combos to find the solution Story is @Nature...

By David Sinclair, PhD
High‑dose Dexamethasone Improves Outcomes in Newly Diagnosed Myeloma
SocialApr 12, 2026

High‑dose Dexamethasone Improves Outcomes in Newly Diagnosed Myeloma

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/GnehXu71Td

By Mike Thompson, MD PhD
NMN Reverses Ovarian Aging in Mice, Human Trials Needed
SocialApr 12, 2026

NMN Reverses Ovarian Aging in Mice, Human Trials Needed

DATA REPRODUCED: In old female mice, NMN restores ovarian follicle reserve in 10 days. Optimal dose was 200-500 mg/kg body weight/day. Equivalent to 35-45 in woman years. Clinical trials are needed 🐭🧓 https://t.co/oVeGUZSaQ0

By David Sinclair, PhD
P&G Brings Biotech Ingredients to Mass‑market Consumer Products
SocialApr 11, 2026

P&G Brings Biotech Ingredients to Mass‑market Consumer Products

P&G doesn't move on new ingredients unless the science is bulletproof and the consumer performance is there. They're moving on biotech. Three R&D leaders from Procter & Gamble are at SynBioBeta 2026 to talk about how bio-derived ingredients are making it into...

By John Cumbers
Seeking Experiences with GTWY Peptide From Β‑Lactolin
SocialApr 11, 2026

Seeking Experiences with GTWY Peptide From Β‑Lactolin

New smart drug peptide alert… (Possibly): who has experience with GTWY peptide isolated from β-lactolin? Research here: https://t.co/Sg7twStXvr

By Ben Greenfield
Combating Rising Anti‑Vaccine Activism Through Science Advocacy
SocialApr 11, 2026

Combating Rising Anti‑Vaccine Activism Through Science Advocacy

Many thanks ⁦@uiowa⁩ for hosting my lectures this week, on our vaccine development program and the dangers of accelerating antivaccine activism in America, also the history of American anti-science movements and latest book #ScienceUnderSiege with @MichaelEMann @PeterHotez https://t.co/3r0XH08iMu

By Peter Hotez
Light‑Powered Nanorobots Capture and Relocate Bacteria Precisely
SocialApr 11, 2026

Light‑Powered Nanorobots Capture and Relocate Bacteria Precisely

Light-driven nanorobots, smaller than a micron, can now hunt, capture, and relocate bacteria with precision, offering new possibilities for targeted manipulation in microbiology and biomedical research. nanotechnology

By Phys.org Threads
Weekly Biotech Roundup: Top Insights From X's Best Accounts
SocialApr 11, 2026

Weekly Biotech Roundup: Top Insights From X's Best Accounts

Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...

By Yair Einhorn
AI‑Designed Enzymes Break Evolution’s Limits for Biomanufacturing
SocialApr 11, 2026

AI‑Designed Enzymes Break Evolution’s Limits for Biomanufacturing

Nature never designed enzymes for industrial manufacturing. It designed them to survive. That mismatch is one of the biggest bottlenecks in biomanufacturing — and most of the industry has been working around it with incremental fixes for decades. Matthew Thompson from Biomatter...

By John Cumbers
Poor Drug Selection Hampers Stroke Treatment Breakthroughs
SocialApr 11, 2026

Poor Drug Selection Hampers Stroke Treatment Breakthroughs

1,026 experimental treatments in acute stroke (2006) "The results question whether the most efficacious drugs are being selected for stroke clinical trials. This may partially explain the slow progress in developing treatments..." https://t.co/WllAIz3Xul

By David Barzilai, MD PhD
Epigenetic Clock Detects Aging and Cancer via Blood Test
SocialApr 11, 2026

Epigenetic Clock Detects Aging and Cancer via Blood Test

This is the future: An epigenetic clock for the simultaneous assessment of biological aging and cancer from a simple, cheap blood test 👏 https://t.co/uzGoZWos9C

By David Sinclair, PhD
Spatial Biology, Single‑cell Profiling, and AI Map T‑cell Immunity
SocialApr 11, 2026

Spatial Biology, Single‑cell Profiling, and AI Map T‑cell Immunity

Towards Spatial Medicine for individualized cancer immunotherapy @SciImmunology "The convergence of spatial biology platforms, single-cell immune profiling, and machine learning is positioning the community to decode how T cell immunity is spatially organized in human tissues and to exploit that organization...

By Eric Topol
Progerin Bridges Premature and Natural Aging, Biomarker Potential
SocialApr 11, 2026

Progerin Bridges Premature and Natural Aging, Biomarker Potential

Progerin expression in humans: implications for natural ageing "These insights may collectively position progerin as a mechanistic link between premature ageing and physiological ageing, positioning it as a potential component of biomarker strategies." https://t.co/KZuV0c7TOK

By David Barzilai, MD PhD
Cell‑free DNA Manufacturing Eliminates Cloning Bottlenecks
SocialApr 11, 2026

Cell‑free DNA Manufacturing Eliminates Cloning Bottlenecks

Your DNA synthesis workflow is probably slowing you down more than you think. Cloning introduces delays, contamination risk, and hard limits on what you can build. Most of the field is still living with these constraints — even as mRNA therapeutics,...

By John Cumbers
Stool Test Detects 90% of Colorectal Cancers
SocialApr 11, 2026

Stool Test Detects 90% of Colorectal Cancers

As a medical school professor, I've watched colorectal cancer screening rely on colonoscopies for decades. That era may be ending. Researchers at the University of Geneva just published a breakthrough in Cell Host & Microbe: a simple stool test that detects...

By Robert Lufkin, MD
Real‑time Biological Data Is the Missing Link for AI
SocialApr 11, 2026

Real‑time Biological Data Is the Missing Link for AI

🧵 Unlocking the true potential of AI and bioinformatics hinges on one missing link: real-time biological data. I saw that Prof. Nikolai Slavov posted this, and that reminds me of how complicated a single cell is. https://t.co/UCUeL2Bdge

By Ming Tang
Choosing Cutoffs for P‑values, Log2
SocialApr 11, 2026

Choosing Cutoffs for P‑values, Log2

🧵“What cutoff should I use for p-value, log2FC, or mito content?” This is the most common question I get. Here's why it’s not simple: https://t.co/A4P37eEwdc

By Ming Tang
China's Biotech Surge Threatens Western Drug Dominance
SocialApr 11, 2026

China's Biotech Surge Threatens Western Drug Dominance

Big Pharma Is Turning to China for the Newest Drug Ideas—China’s biotechs are faster and have lower costs, and its drug research threatens to soon overtake the West’s @Loftus https://t.co/YszgDfNlwc https://t.co/YszgDfNlwc

By Jonathan Cheng
IL6R Protects, IL6 Harms: Genetic Proof of Survival Impact
SocialApr 11, 2026

IL6R Protects, IL6 Harms: Genetic Proof of Survival Impact

Causal effects of inflammation on long-term mortality: A mendelian randomization study 🔑"The IL6/IL6R axis has a causal impact on human survival through cardiovascular mechanisms: IL6R exerts a protective effect, whereas IL6 is detrimental." https://t.co/0TwQldDrQe

By David Barzilai, MD PhD
One‑sentence AI Pipeline Transforms Drug Discovery Workflow
SocialApr 11, 2026

One‑sentence AI Pipeline Transforms Drug Discovery Workflow

What if your next drug discovery pipeline started with one sentence, not 6 months of scripting? In this latest deep dive with @scispace, I saw a shift that feels bigger than incremental AI gains. Upload single-cell data and get clustered cell types,...

By Ron van Loon
Aging
SocialApr 11, 2026

Aging

RIP Dr Skulachev who made serious contributions to the ROS theory of aging. Unfortunately, no FDA-approved drug out of his work yet. One of my goals is to have several FDA approved drugs before or after I die. Papers and...

By Alex Zhavoronkov, PhD
Human Cells Lag Far Behind Yeast in Large DNA Integration
SocialApr 11, 2026

Human Cells Lag Far Behind Yeast in Large DNA Integration

“Ultra large” in this paper is 8 kb 😭 > shows how far we are from achieving the sort of SynBio we routinely do in yeast in primary human cells. 50 kb integrations are fairly routine in yeast

By Tom Ellis
MIT Discovers Hundreds of Bacterial CRISPR-Like Tools
SocialApr 11, 2026

MIT Discovers Hundreds of Bacterial CRISPR-Like Tools

MIT Mined Bacteria for the Next CRISPR—and Found Hundreds of Potential New Tools https://t.co/n4cJpB8dVk https://t.co/Vq57AKw6XD

By Brian Ahier
Self‑immunized Man’s Blood Yields Universal Antivenom
SocialApr 11, 2026

Self‑immunized Man’s Blood Yields Universal Antivenom

A truck mechanic from Wisconsin spent 18 years injecting himself with venom from the world's deadliest snakes. 700 doses. 200+ bites. He taught himself immunology from a textbook. His name is Tim Friede. His blood may end up saving hundreds of...

By John Cumbers
Longevity Strategies Miss Deeper Levels of Aging
SocialApr 10, 2026

Longevity Strategies Miss Deeper Levels of Aging

Are we targeting aging the wrong way? In this interview with Peter Fedichev (@fedichev), CEO of Gero, we discuss why many longevity interventions may only be tackling “level 1” aging. https://t.co/jRnuYr3dFN

By Eleanor Sheekey, PhD
Dynamic Enzyme Complex Maps Nicotine Biosynthesis in Wild Tobacco
SocialApr 10, 2026

Dynamic Enzyme Complex Maps Nicotine Biosynthesis in Wild Tobacco

The complete biosynthetic pathway of nicotine in wild tobacco has been mapped, revealing a dynamic enzyme complex that orchestrates the final steps and transport of this alkaloid, offering new insights for synthetic biology and plant defense mechanisms. plantbiology

By Phys.org Threads
Reprogrammed Tregs Turn Pancreatic Tumors Immunotherapy‑Friendly
SocialApr 10, 2026

Reprogrammed Tregs Turn Pancreatic Tumors Immunotherapy‑Friendly

Reprogramming regulatory T cells within pancreatic tumors may transform them from immune suppressors into supporters of anti-tumor activity, offering a potential strategy to enhance immunotherapy effectiveness in this challenging cancer. immunotherapy

By Phys.org Threads
Biotech IPOs Open as Hemab Goes Public
SocialApr 10, 2026

Biotech IPOs Open as Hemab Goes Public

Biotech IPO gates are opening. Congrats also to @JMaraganore (Chair) and Benny Sorensen (CEO) of Hemab, and best of luck.

By Brad Loncar
Explore Rapamycin's Role in Aging at UArizona
SocialApr 10, 2026

Explore Rapamycin's Role in Aging at UArizona

If you’re in Tucson next week, I’ll be giving a talk at the University of Arizona College of Pharmacy (@UAZPharmacy) on the science behind rapamycin and aging. We’ll cover what we know, what we don’t, and where the field is...

By Matt Kaeberlein, PhD
REPL RP1 Melanoma Trial Flawed; New CRL
SocialApr 10, 2026

REPL RP1 Melanoma Trial Flawed; New CRL

I've never covered the REPL RP1 data in melanoma, mainly due to dislike of the trial design w/ its lack of a monotherapy arm. Sometimes you can see where things are likely headed and kicking a dog when it's down...

By Sally Church
FDA Approves First Gene Therapy for LAD‑I Children
SocialApr 10, 2026

FDA Approves First Gene Therapy for LAD‑I Children

FDA approves first gene therapy, Kresladi, offering a breakthrough treatment for children with the rare immune disorder LAD-I https://t.co/ezWPPEgtd0

By Liz Parrish
Live CEO Interviews From Raymond James Biotech Symposium
SocialApr 10, 2026

Live CEO Interviews From Raymond James Biotech Symposium

Programming note: On Tuesday of next week I'll be broadcasting @BiotechTV interviews from the Raymond James Biotech Symposium in New York. Current confirmed CEO interviews: $SEPN $AKBA $WVE $VERA $DYN $KRRO (and maybe more). Let me know any questions for...

By Brad Loncar
Ezetimibe Shows Unexpected Potential to Prevent Alzheimer’s
SocialApr 10, 2026

Ezetimibe Shows Unexpected Potential to Prevent Alzheimer’s

Ezetimibe might help prevent Alzheimer's disease... but not in the way that you think. These data really caught me off guard. But the data are the data. (long-form video linked below)

By Nick Norwitz MD PhD
OCE's Objections Caused Rejection, Not Vinay Prasad
SocialApr 10, 2026

OCE's Objections Caused Rejection, Not Vinay Prasad

$REPL my read of the RP1 CRL suggests OCE (CDER) took the lead in the review. Their objections led to the first rejection, as I previously reported, and nothing Replimune submitted for the second review was enough to support...

By Adam Feuerstein
Replimune's FDA‑targeted Skin Cancer Drug Faces Another Rejection
SocialApr 10, 2026

Replimune's FDA‑targeted Skin Cancer Drug Faces Another Rejection

Replimune $REPL skin cancer drug that became FDA flashpoint is rejected again https://t.co/7aOfKy8vC7 via @Jasonmmast

By Adam Feuerstein
Psychedelic Therapies May Outpace GLP‑1s Commercially
SocialApr 10, 2026

Psychedelic Therapies May Outpace GLP‑1s Commercially

I believe the commercial potential of #psychedelic therapies is likely to exceed that of GLP-1s. $ATAI $CMPS $DFTX

By Christian Angermayer
Optical Genome Mapping Enhances AML Classification and Treatment
SocialApr 10, 2026

Optical Genome Mapping Enhances AML Classification and Treatment

Optical genome mapping [OGM] improves the accuracy of classification, risk stratification, & personalized treatment strategies for Pts w/ acute myeloid leukemia [Jul 17, 2024] @sanamloghavi et al. @AjHematology https://t.co/R5ZLgolhuj #AMLsm #leusm #PrecisionMedicine #oncopath https://t.co/kX7KUJLK0L

By Mike Thompson, MD PhD
Sex Drives Distinct Immune Aging Patterns and Disease Risks
SocialApr 10, 2026

Sex Drives Distinct Immune Aging Patterns and Disease Risks

The way our immune cells age differs substantially by sex, from single-cell analysis of ~1,000 people. Implications for propensity for autoimmune diseases (women), vulnerability to cancer (men), immunosenescence and inflammaging @NatureAging https://t.co/GjcuZ8luNM

By Eric Topol
Personalized CRISPR Fixes Baby KJ’s Genetic Defect
SocialApr 10, 2026

Personalized CRISPR Fixes Baby KJ’s Genetic Defect

In just 6 months a team at @ChildrensPhila & @PennMedicine designed a personalized CRISPR based Rx to correct the single misspelled letter in Baby KJ’s DNA that results in CPS1 deficiency. Recent advances in mRNA science & CRISPR gene...

By Daniel Kraft, MD
Biotech IPO Surge Expected; List on NYSE
SocialApr 10, 2026

Biotech IPO Surge Expected; List on NYSE

Getting to know the @NYSE and Johanna and Eric has been a highlight of mine since their earliest support of BiotechTV. I have no doubt we will see a strong IPO pipeline for biotech this year, and I hope you...

By Brad Loncar
Ultrasound Enables Non‑Invasive Control of Body Cells
SocialApr 10, 2026

Ultrasound Enables Non‑Invasive Control of Body Cells

"Sonogenics" is an emerging scientific field that uses ultrasound to non-invasively control and manipulate specific cells in the body, such as neurons or heart cells

By Daniel Kraft, MD
NMN Daily Restores NAD, Supports Healthy Aging
SocialApr 10, 2026

NMN Daily Restores NAD, Supports Healthy Aging

David Sinclair takes 1 gram of NMN every single day. Here's why. As you age, your body loses up to 50% of a molecule called NAD. NAD is a molecule that acts like fuel powering your sirtuin genes - the genes responsible...

By John Cumbers
Young Mitochondria Transplants Could Reverse Aging and Disease
SocialApr 10, 2026

Young Mitochondria Transplants Could Reverse Aging and Disease

What if aging, ALS, Parkinson's, stroke, and diabetes all share a single upstream cause — and the fix is a transplant the size of a bacterium? Dr. Catherine Baucom and Van Hipp of MitoSense explain how injecting healthy young mitochondria...

By Robert Lufkin, MD
Regeneration Depends on Environment, Oxygen, and Epigenetics
SocialApr 10, 2026

Regeneration Depends on Environment, Oxygen, and Epigenetics

Awakening latent regeneration in mammals “regeneration is not simply a fixed genetic trait but rather a state that is dependent on the extracellular environment, oxygen sensing, and epigenetics.” https://t.co/HtTXENUEur

By David Barzilai, MD PhD
Blocking 15-PGDH Reverses Age‑Related Cartilage Loss
SocialApr 10, 2026

Blocking 15-PGDH Reverses Age‑Related Cartilage Loss

As a medical school professor, I was taught that lost cartilage is gone forever. Stanford just proved that wrong. Researchers discovered that blocking a single protein (15-PGDH) -- which rises as we age -- can actually REGROW joint cartilage in aging mice. The...

By Robert Lufkin, MD
New GLP‑3 Drug Reta May Target Fat, Spark Hunger
SocialApr 10, 2026

New GLP‑3 Drug Reta May Target Fat, Spark Hunger

Like it or not, GLP-1-based weight loss drugs are here to stay. 1/2) What's more, people are experimenting with newer evolutions, like "reta" (retatrutide/GLP-3). As an MD PhD & metabolism scientist, I decided to start my own experiment to help answer...

By Nick Norwitz MD PhD
Decoding ORR: What RECIST v1.1 Means for Investors
SocialApr 10, 2026

Decoding ORR: What RECIST v1.1 Means for Investors

Investors will often see ORR quoted or displayed for oncology clinical trial results for solid tumors Here's what the CRs/PRs/SDs mean at a high level These are assessed on scans I'm using RECIST v1.1 definitions #learnbiotechinvesting #biotech #investing #BiotechPrometheus https://t.co/eZb86TcoLL

By Biotech Investor